Overview

In the KOSMOS study, various cancer specialists including medical oncologists, pathologists, and bioinformaticians collaborate in a Molecular Tumor Board to analyze patients' NGS (Next-Generation Sequencing) test results and clinical information, recommending the most appropriate treatment options for each patient. Based on the Molecular Tumor Board's recommendations, patients will either participate in suitable clinical trials, receive treatment with investigational medicinal products supplied through pharmaceutical company support via KOSMOS, or undergo precision medicine personalized treatments using other anticancer agents. The KOSMOS study aims to collect NGS results, clinical information, and treatment outcomes to build a public database that can be utilized for cancer diagnosis and therapeutic research. This study is supported by the Cancer Conquest Project of the National Cancer Center and represents a nationwide collaborative project involving government, academia, hospitals, and industry stakeholders, including the Korea Health Industry Development Institute, National Cancer Data Center at the National Cancer Center, domestic and international pharmaceutical and biotechnology companies, and genomic testing companies.

Study Scheme for trial